While functional experiments are needed to confirm these links, our data provide a novel framework: targeting the FLI1-PARP14 axis could not only alleviate UC activity by reducing immune infiltration but also potentially lower CRC risk by mitigating chronic inflammation. Here, PARP14 is linked to colorectal carcinoma.